RxDoctor Payments Data

Carlos Martinez Rivera, MD

Endocrinology, Diabetes & Metabolism · Mayaguez, PRNPI 1356330310

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,020 of the $8,835 with a category attached, or 79.5%. Johnson & Johnson accounts for 86.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $7,388 and has fallen 97.0% since, to $220 in 2025.

$8,835in general payments, 2019–2025

Across 75 payments — averaging $117.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$8K
  • Sanofi-aventis U.S. LLC$406
  • AbbVie$237
  • Boehringer Ingelheim$193
  • Abbott$154
  • AstraZeneca$63
  • plus $128 from 4 others

What the payments were for

  • Consulting fees$3754%
  • Speaking & faculty fees$7,02079%
  • Travel & lodging$741%
  • Food & beverage$1,36015%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,835 in reported general payments places this provider in the 75th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$19,270
Medicare patients
95
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol1,548$1,104,303
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog1,506$810,554
TrulicityDulaglutide630$636,634
Humalog Kwikpen U-100Insulin Lispro1,783$437,259
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog460$432,896
JardianceEmpagliflozin617$431,722
SynthroidLevothyroxine Sodium5,342$405,924
Xigduo XrDapaglifloz Propaned/Metformin345$244,766
Soliqua 100-33Insulin Glargine/Lixisenatide187$182,252
Humulin R U-500 KwikpenInsulin Regular, Human91$153,832
Synjardy XrEmpagliflozin/Metformin Hcl207$151,437
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres12$108,608
TradjentaLinagliptin174$104,594
Humulin R U-500Insulin Regular, Human50$97,319
HumalogInsulin Lispro459$67,363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$63$1,104,3031,548 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Glyxambi, Synjardy$193$738,3091,061 claims
AbbVieSynthroid$237$405,9245,342 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$406$219,231592 claims
Novo NordiskOzempic$34$25,28324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →